Featured Research

from universities, journals, and other organizations

Potential anti-TNF response biomarker identified

Date:

June 12, 2014

Source:

European League Against Rheumatism

Summary:

DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. This data bring clinicians a step closer to being able to personalize a patient's treatment pathway.

Share This

DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies.1 These data, presented today at the European League Against Rheumatism Annual Congress (EULAR 2014), bring clinicians a step closer to being able to personalise a patient's treatment pathway.

Related Articles

Anti-TNF therapies have proved a huge advance for the treatment of rheumatoid arthritis and have transformed the treatment of inflammatory arthritis for millions of people around the world. However, only 20-40% of patients achieve a good response according to EULAR criteria.

"It can take several years to identify the most effective treatment for an RA patient. This is not only costly in terms of the financial burden, but also in terms of patient outcomes and the irreversible joint damage that is being done," said Amy Webster, University of Manchester, United Kingdom. "Because of this, the identification of biomarkers that can predict a patient's response to a treatment is an important area of research which will allow the most effective treatment for each patient to be identified early in the course of the disease."

She continued, "Based on recent studies showing a role for epigenetics in RA and other autoimmune disorders, we hypothesised that epigenetic changes, such as DNA methylation, may provide potential biomarkers of response to anti-TNFs."

RA is a chronic systemic disease that affects the joints, connective tissues, muscle, tendons, and fibrous tissue. A disabling condition that often causes pain and deformity, symptoms of RA tend to appear between the ages of 20 and 40. The prevalence of RA globally varies between 0.3% and 1% and is more common in women and in developed countries. Within 10 years of onset, at least 50% of patients in developed countries are unable to maintain a full-time job. 1In this study, patients were selected from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) longitudinal cohort based on having an extreme response phenotype after three months of treatment with etanercept or adalimumab. Of the patients in the study, 36 patients were good responders to etanercept and 45 to adalimumab as defined by having an endpoint of DAS28<2.6. Poor responders to etanercept (35) and adalimumab (27) were defined by having an improvement of <0.6 or between 0.6-1.2 with an endpoint DAS28 of >5.

DNA from each patient was sampled before therapy was initiated. Following bisulfite conversion of the DNA, an epigenome-wide association study was conducted using the HumanMethylation450 BeadChip (Illumina) to determine unmethylated versus methylated cytosines within the DNA. The results from each drug were analysed separately and together using the minfi package in R and probes with a detection-p value > 0.01 were removed. Differentially methylated positions between responders and non-responders were identified using the F-test following quantile normalisation.

In the etanercept study, four CpG* sites showed differential DNA methylation that passed a false discovery rate of 0.05, while in the adalimumab study less significant results were observed. The most differentially methylated position in etanercept patients mapped to the LRPAP1 gene (p=1.46x10-8). This gene encodes a chaperone of low density lipoprotein receptor-related protein 1 (LRP1) which is known to influence TGF-β activity. Technical validation of methylation at this site by pyrosequencing showed very good correlation (Spearmans r=0.8). In the adalimumab patients, the most differentially methylated position maps to the PDZD8 gene. Joint analysis of the two drugs together identified a differentially methylated region overlapping the CRYZ and TYW3 genes, which have previously been associated with inflammation and Type 2 diabetes.

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 3, 2015 — Limp or firm, your handshake conveys subliminal social cues. Now, research reveals it also transmits chemical signals that could explain why the greeting evolved in the first ... full story

Mar. 3, 2015 — Loneliness brought about by the death of a spouse can trigger a wider network of depression-like symptoms, a study has found, but authors suggest that doctors are often too quick to attribute these ... full story

Mar. 3, 2015 — Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT), a recent study has found. ... full story

Mar. 3, 2015 — Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to new research. The scientists conducted a comprehensive survey of ... full story

Mar. 3, 2015 — Scientists have succeeded in producing cartilage formed from embryonic stem cells that could in future be used to treat the painful joint condition osteoarthritis. With their huge capacity to ... full story

Mar. 3, 2015 — Everyone worries about losing their memory as they grow older—memory loss remains one of the most common complaints of the elderly. But the molecular reasons behind the processes remain unclear, ... full story

Mar. 3, 2015 — A strong link has been made between subthreshold manic episodes and likelihood of developing bipolar disorder in children of parents with bipolar disorder. The study’s findings could improve ... full story

Mar. 2, 2015 — Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970, a study has found. "Our results suggest that cancer care ... full story

Mar. 2, 2015 — In the first study of its kind since the 1920s, rats in New York City were found to carry a flea species capable of transmitting plague pathogens. Among them: 500-plus Oriental rat fleas, notorious ... full story

Mar. 2, 2015 — A newly published study is the first to report an association between bisphenol-A (BPA), a common plasticizer used in a variety of consumer food and beverage containers, with autism spectrum disorder ... full story

Featured Videos

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) — After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3)
Video provided by AP

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) — A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3)
Video provided by AP

Related Stories

Mar. 5, 2013 — Although patients with rheumatoid arthritis (RA) have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other ... full story

Feb. 14, 2013 — Scientists have presented a new therapy approach for the treatment of rheumatoid arthritis (RA), a chronic form of joint inflammation. The new therapy study was especially directed at patients who ... full story

Aug. 8, 2012 — New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab ... full story

May 27, 2011 — Newer biologic treatments, including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi) and etanercept (Enbrel), used in patients with arthritis do not ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.